We have screened 22 bladder tumour-derived cell lines and one normal urothelium-derived cell line for genome-wide copy number changes using array comparative genomic hybridization (CGH). Comparison of array CGH with existing multiplex-fluorescence in situ hybridization (M-FISH) results revealed excellent concordance. Regions of gain and loss were defined more accurately by array CGH, and several small regions of deletion were detected that were not identified by M-FISH. Numerous genetic changes were identified, many of which were compatible with previous results from conventional CGH and loss of heterozygosity analyses on bladder tumours. The most frequent changes involved complete or partial loss of 4q (83%) and gain of 20q (78%). Other frequent losses were of 18q (65%), 8p (65%), 2q (61%), 6q (61%), 3p (56%), 13q (56%), 4p (52%), 6p (52%), 10p (52%), 10q (52%) and 5p (43%). We have refined the localization of a region of deletion at 8p21.2-p21.3 to an interval of approximately 1 Mb. Five homozygous deletions of tumour suppressor genes were confirmed, and several potentially novel homozygous deletions were identified. In all, 15 high-level amplifications were detected, with a previously reported amplification at 6p22.3 being the most frequent. Real-time PCR analysis revealed a novel candidate gene with consistent overexpression in all cell lines with the 6p22.3 amplicon.
Introduction
Many genetic changes associated with tumour development and progression involve region-specific gain or loss of DNA copy number, the genomic location of which identifies the position of key genes involved. Thus, regions of DNA amplification commonly harbour oncogenes and regions of deletion, tumour suppressor genes. Several methods have been applied to detect such copy number changes in tumours including classical cytogenetics, interphase fluorescence in situ hybridization (FISH), Southern blot analysis, quantitative polymerase chain reaction (PCR)-based assays and comparative genomic hybridization (CGH). The location of many tumour suppressor genes has also been identified by loss of heterozygosity (LOH) analysis. Commonly but not invariably, copy number loss accompanies LOH and this in turn is associated with mutation in the retained copy of a target gene, indicating likely biallelic inactivation.
All of these approaches have been applied to transitional cell carcinoma (TCC) of the bladder. Many CGH studies of bladder cancer have been published (e.g. Kallioniemi et al., 1995; Voorter et al., 1995; Richter et al., 1997; Hovey et al., 1998; Simon et al., 1998; Richter et al., 1999; Simon et al., 2000) . These have provided a great deal of information, including the identification of a number of genomic regions of DNA amplification that contain known or candidate oncogenes including cyclin D1 (CCND1) on 11q13 Bringuier et al., 1996) , ERBB2 on 17q21 and MDM2 on 12q14-q15 (Simon et al., 2002) . The locations of tumour suppressor genes in TCC have largely been identified by LOH analysis. Known and candidate genes identified in this way include CDKN2A, DBC1and TSC1 on chromosome 9, PTEN on 10q, RB on 13q and TP53 on 17p (reviewed in Knowles, 1999) .
Although conventional CGH to metaphase spreads has provided a wealth of information on genome-wide copy number changes in tumours, its resolution is routinely limited to regions greater than 10 Mb although with advanced methods it is possible to detect deletions in the order of 3 Mb (Lichter et al., 2000) and it is unable to resolve regional single-copy number gains or losses and their associated breakpoints in an aneuploid genetic background. Once copy number changes have been mapped, identification of candidate genes is limited by the lack of precise relationship of the data to the human genome sequence. Until recently, LOH analysis has also been limited in resolution by the density and location of markers used in the analysis, although the development and successful application of high-density SNP arrays to the study of bladder cancer should now overcome this limitation (Primdahl et al., 2002; Hoque et al., 2003) .
TCCs fall into two groups based on histopathologic and clinical findings. The majority of tumours at presentation (B80%) are noninvasive, papillary lesions that commonly recur, often over a long time course but infrequently progress to invade muscle (10-15%). Patients with this so-called 'superficial' disease may return to the clinic many times but have a good overall prognosis. In contrast, approximately 20% of tumours are muscle invasive at presentation and these have a poor prognosis (50% 5-year survival for pT2 tumours). Much of the available genetic information on TCC relates to the latter group of tumours, and in low-grade superficial tumours, only alterations of chromosome 9 and mutation of the FGF receptor 3 (FGFR3) are common (Billerey et al., 2001; Cairns et al., 1993) . There are at present no reliable molecular genetic markers that predict tumour recurrence, risk of progression or response to therapy in either group of tumours. We hypothesize that more genetic alterations remain to be identified and that high-resolution screening of the genome may identify critical alterations that have been missed by the methods applied to date.
The development of array-based methods for CGH (Hodgson et al., 2001; Pinkel et al., 1998; Simon et al., 2002; Veltman et al., 2002) provides high-resolution detection of copy number changes limited only by the size and spacing of the large insert clones included in the array. The quantitative data collected should also allow the identification of single-copy changes in highly aneuploid tumour cells. Here we have used an array comprising DOP-PCR products from a set of 3040 clones spaced at approximately 1Mb intervals (Fiegler et al., 2003) to examine the genome of 23 bladderderived cell lines in common use and for which some genomic information was available including microsatellite typing and multiplex-fluorescence in situ hybridization (M-FISH) analyses. This has allowed us to test the ability of the array to detect known genetic changes and to identify novel alterations that have been undetected in the many previous studies on these cell lines. Precise localization of a known amplification on 6p22 (Bruch et al., 2000) allowed direct identification of candidate genes from the Ensembl Human Genome Browser, one of which is a novel gene with consistent overexpression in all cell lines with 6p22 amplification. 1p32.3-qter, 7, 16p11.2-pter, 19 2q24.1-qter, 4pter-q22.1, 4q22.1, 4q22.1-qter, 6, 8, 11, 13q12.11-qter, 14q11.2-qter, 15q11.1-q21.1, 16q12.1-qter, 18 5637 3p25, 5p12-pter, 6p22.3, 7, 8q23.3-qter, 9q31.1-qter, 11q13.1-q13.3, 11q21-q22.1, 11q22.1-q22.3, 14q11.2-qter, 17q11.2-q24.2, 18q11.2-q12.1, 20q11.21-qter 3p12.2-p24.3, 3p25.3-pter, 4, 5q11.2-q33.2, 6p22.3-pter, 6p22.3-q16.3, 8pter-q23.3, 10, 13q12.11-q12.2, 13q13.1-q14.11, 13q14.11-q14.13, 13q14.13-q21.32, 16, 18q12 13-q21.3, 9q13-qter, 10p13-pter, 11p11.2-pter, 13q14.3-q21.2, 13q21.31-q32.3, 13q33.1-qter, 20p11.21-pter 1q21.3-q23.2, 2q13-qter, 4q28.2-qter, 6p22.3-p22.1, 8p12-pter, 10q23.31-qter, 12p11.21-p12.3, 12p12.3-pter, 12q12-q13.12, 13q13.2-q14.3, 14q11.2-qter, 17, 19, 22q13.2-qter J82 3p12.1-q21.1, 3q21.21-q21.3, 3q23-q26.1, 3q26.1-qter, 5p12-pter, 6p21.32-pter, 9, 11p15.2-pter, 11p15.2-q21, 13q12.11-q14.11, 13q21.1-qter, 18p11.32-pter, 20q11.21-q11.22, 20q11.22-q13.12, 20q13.13-q13.2, 21q11.2-q22.3, 21q11.2-qter, 22q11.23-qter 2p16.1-pter, 2q35-qter, 4p14-q32.1, 8p12-p21.3, 8p21.3-pter, 10p11.21-qter, 11q21-qter, 14q22 4, 9, 11q14.1, 16, 2, Figure 2 shows array CGH results for RT112 presented as individual chromosome plots of log 2 ratio of normalized Cy3 : Cy5 intensities versus distance along the chromosome (Mb) and a schematic representation of the corresponding chromosomal rearrangements identified using M-FISH. Chromosomal copy number gains and losses identified using the two methods are summarized in Table 2 . Array CGH and M-FISH data corresponded well with respect to chromosomal copy number changes delineated in RT112. Two deleted regions (2q22.1-q23.1 and 5q11.1-q11.2) were detected using array CGH but not by M-FISH and, conversely, deletion of 21p was detected using M-FISH but not by array CGH. Single-copy deletion of the 2q region was confirmed by FISH to metaphase spreads using a labelled BAC clone (bA279M2) from the deleted region as a probe (Figure 4a and 4b) . Figure 3a shows array CGH results for RT4 presented as individual chromosome plots of log 2 ratio of normalized Cy3 : Cy5 intensities versus distance along the chromosome (Mb), and a schematic representation of the corresponding chromosomal rearrangements identified using M-FISH is shown in Figure 3b . Again, array CGH and M-FISH data corresponded well but some differences were observed (Table 3) . Array CGH indicated deletion of the region 6q25.3-qter and gain of 15q25.2-qter whereas the chromosome rearrangement in this region was scored as a balanced translocation by M-FISH. A small deletion of 11q14.1 was detected using array CGH but not M-FISH. Conversely, losses of 13p, 14p and 21p, and gain of 15p were detected using M-FISH but not array CGH as the p-arms of acrocentric chromosomes are not covered on the array. Array CGH results showed loss of chromosome 13; however, the level of loss was outside our selected cutoff limits for significant gains and losses (above or below SW1710 5q23.3-qter, 7p15.3-qter, 8q24.13-qter, 9q31. Five previously reported homozygous deletions of gene regions containing tumour suppressor genes were detected using array CGH. These included deletion of chromosome regions 9p21.3 containing CDKN2A (DSH1 and SD) (Williams et al., 2002) , 9q33.1 containing DBC1 (DSH1) (Williams et al., 2002) and a region on 10q that contains PTEN (J82 and UM-UC-3) . Figure 4 (c-f) shows the respective individual chromosome plots for these cell lines with the positions of homozygously deleted clones clearly visible as high-level 'dropouts'. Several novel potential homozygous deletions involving one or two clones on the array were detected on chromosomes 2, 3, 4, 7, 9, 11, 12, 13, 14, 15, 21 and X, and these are currently being confirmed by other methods. Fifteen regions of high-level chromosomal amplification were detected ( Figure 1 , Table 1 ) with an average of 0.8 amplifications (range 0-4) per cell line. Cell lines SD and SCaBER had the highest number of amplifications (four and three, respectively). These two cell lines were also among those with the most marked chromosomal aberrations (Table 1 ). The majority of amplifications detected were seen in only one cell line with the exception of those in chromosome regions 3q11.1 and 6p22.3 which were detected in three (647-V, SD, VMCUB3) and four (5637, HT1376, JO 0 N, TCC-SUP) cell lines, respectively (Figure 5a and 5b). The presence of the 3q11.1 amplicon in cell line 647-V was confirmed by metaphase-FISH using a PAC clone (dJ447J13) from the amplified region and a clone from the flanking nonamplified region as a probe (Figure 6a ). Amplified material was detected on one large chromosome identified as chromosome 3 using a probe specific for chromosome 3 centromeres (Figure 6b ). The presence of the 6p22.3 amplicon in cell line 5637 was confirmed by metaphase-FISH using a BAC clone (bA204E9) from the amplified region and a clone (RP11-349A12) from the flanking non-amplified region as probes. Amplified material was detected on two large chromosomes (Figure 6c ). Hybridization with a probe specific for chromosome 6 centromeres indicated that neither of these chromosomes was chromosome 6 (Figure 6d ). Existing M-FISH data for 5637 have indicated that chromosome 6 material is present on chromosomes 3 and 5 (Williams et al., in preparation). On this basis, we performed M-FISH using a probe specific for chromosome 3 centromeres and it was confirmed that one of the chromosomes carrying amplified material was chromosome 3 (Figure 6e ). We have yet to confirm that the other chromosome carrying the 6p22.3 amplicon is chromosome 5 due to the lack of a probe specific for Figure 3 (a) Array CGH profile of bladder cancer cell line RT4 presented as individual chromosome plots of log 2 ratio versus distance along chromosome (Mb) (b) Schematic representation of chromosomal rearrangements identified in bladder cancer cell line RT4 using M-FISH. Numbers adjacent to chromosomes indicate the chromosome of origin for translocated material. Four copies of chromosome 4 were observed in only 12% of metaphases examined chromosome 5 centromeres. Minimum regions of amplification were defined for both 6p22 and 3q11 amplicons, and candidate genes were identified using the Ensembl database ( Figure 5 ). Known genes mapping to the 3q11.1 region include CGGBP1, HTR1F and the transcription factor POU1F1. The 6p22.3 region was chosen for further study as this represented the most frequent amplification and has previously been reported in bladder tumours and cell lines analysed by conventional CGH (Kallioniemi et al., 1995; Bruch et al., 1998 Bruch et al., , 2000 . Expression of 6p22.3 candidate genes E2F3, SOX4, Q9H1N9, PRL and NM_017774 was analysed using real-time quantitative PCR. PRL expression could not be detected, and levels of expression of SOX4 and Q9H1N9 were not related to possession of the 6p22.3 amplicon (data not shown). The level of expression of NM_017774 and E2F3 relative to control genes was measured and a relationship between presence of the amplicon and elevated expression of both genes was observed. This was most striking for NM_017774, the four cell lines with amplification of the gene showing significantly increased expression compared to all other tumour cell lines and normal urothelial cells (Figure 7 ).
Discussion
Array CGH is a powerful approach for genome-wide detection of DNA copy number changes and, when applied to tumour DNA, presents the possibility of high-resolution mapping of multiple genetic alterations within a single tumour. In addition to highly improved resolution compared with conventional CGH, arraybased CGH has the advantage of higher throughput. This allows relatively rapid assessment of panels of DNA samples. Here we have screened for genome-wide copy number changes in 22 bladder tumour-derived cell lines and one normal urothelium-derived cell line. As some of these lines were already well characterized by other methods, we have been able to rigorously test the performance of the arrays in terms of both resolution and their ability to identify known levels of copy number change in aneuploid cells. We have also identified previously unknown copy number changes that identify the location of genes that may contribute to the initiation and progression of bladder cancer.
Comparison of array CGH with existing M-FISH results (Williams et al, in preparation) and other genomic data that was available for 17 of the cell lines revealed excellent concordance and this was exemplified well by the data presented for RT4 and RT112. Regions of gain and loss were generally defined more accurately by array CGH and several small regions of deletion were detected that had not been identified by M-FISH, including a previously unreported interstitial deletion of 2q22.1-q23.1 in RT112. In these cases, it is likely that deleted regions were too small to be detected by M-FISH. RT4 has a near tetraploid karyotype and we were able to detect all single copy changes. The ability to detect single-copy changes in an B4n aneuploid background will be crucial in the application of array CGH to the study of tumour specimens that are frequently aneuploid, may be heterogeneous with respect to ploidy levels and even after careful microdissection contain some contaminating normal DNA that could mask the detection of low copy number tumour-specific features.
When tumour DNA is hybridized with a diploid control, all regions with a copy number identical to the modal haploid equivalent of the tumour appear as if diploid (0) on a log 2 ratio plot. However, single-copy changes result in different log 2 ratio changes according to ploidy. Thus, single-copy changes in RT4 which has an B4n content appear as 0.25 increments on a log 2 scale. As we knew the modal chromosome number for many of the cell lines analysed, we were able to confirm for each cell line that the incremental changes in log 2 ratio reflected the known ploidy. Where ploidy is known, it would be possible to plot the results on different scales to reflect this but in future studies of tumour tissues, this information will not be known. With such unknowns, the amplitude of log 2 changes will provide a useful measure of likely overall ploidy (0.5, diploid, 0.33, triploid, 0.25, tetraploid, etc) .
We detected numerous genetic changes, many of which were compatible with previous results from conventional CGH and LOH analyses on bladder tumour samples. This gives confidence that these bladder tumour-derived cell lines, some of which are very widely used, reflect the tumour cell of origin at the genetic level. The most frequent copy number loss involved chromosome 4 and 4q (83%) with minimum regions of deletion at 4q13.1 and 4q31.3. Using conventional CGH, Koo et al. (1999) identified loss of 4q13-q23 in approximately 20% of bladder tumours studied. LOH of both 4p and 4q has also been reported (Elder et al., 1994; Polascik et al., 1995) with a minimum region of LOH at 4q33-q35 (Polascik et al., 1995) coincident with the small deletion found here in HT1376.
We identified loss of 5q in 43% of cell lines. Conventional CGH of bladder tumours has also found frequent deletion of 5q (Voorter et al., 1995; Richter et al., 1997 Richter et al., , 1999 Simon et al., 1998 Simon et al., , 2000 and putative tumour suppressor genes have been implicated based on LOH analysis (Miyamoto et al., 1996; Bohm et al., 1997; von Knobloch et al., 2000) . The minimum region of loss detected here was 5q11.1-q11.2, which does not overlap with regions mapped in these previous studies. Loss of 5q is often seen in association with gain of 5p (Koo et al., 1999; Voorter et al., 1995) implicating genes on both chromosome arms. We detected gains of 5p in 10 out of 23 cell lines (43%), with associated losses of 5q being observed in five of these. The application of array CGH on a series of tumour samples should now allow these complex alterations to be resolved with greater precision.
Frequent loss of 8p has been detected using conventional CGH and FISH analysis of bladder tumours (Richter et al., , 1998 Wagner et al., 1997; Simon et al., 2000) and is associated with tumour progression in vivo. LOH studies have implicated several tumour suppressor loci on 8p at 8p23, 8p22, 8p21 and 8p11-p12 (Takle & Knowles, 1996; Ohgaki et al., 1999; Choi et al., 2000; Muscheck et al., 2000) . Here we detected loss of 8p in 65% of cell lines and refined the localization of a region of deletion at 8p21.2-p21.3 identified previously in bladder (Choi et al., 2000) to an interval of approximately 1Mb within which mutation screening of candidate genes can now be initiated. Gain of 8q is also common in bladder cancer where it has been associated with tumour progression Wagner et al., 1997) . Associated loss of 8p and gain of 8q was detected in nine out of 23 cell lines in the present study and an amplicon at 8q22 in VMCUB3 was as described previously by Bruch et al. (1998) . Our estimation of the size of the amplicon is approximately 4 Mb, within which candidate genes can now be assessed.
LOH and/or under-representation of chromosome 9 is the most frequently described genetic alteration in TCC (450%). The common loss of an entire copy of chromosome 9 with or without reduplication indicates the presence of tumour suppressor genes on both 9p and 9q, and candidate genes have been identified in several regions including 9p21 (CDKN2A) (Williamson et al., 1995) , 9q12-q31 (PTCH) (Aboulkassim et al., 2003) , 9q32-q33 (DBC1) (Habuchi et al., 1998) and 9q34 (TSC1) (Hornigold et al., 1999) . Here, abnormalities involving complete or partial loss of 9p and/or 9q (including small regions of homozygous deletion) were observed in 43% of cell lines although they were not among the most frequent copy number changes detected. However, we have previously shown that although monosomy 9 is frequent in near-diploid papillary TCC (Fadl-Elmula et al., 2000) , reduplication of a single parental homologue appears to be common in cell lines derived from more aggressive tumours (Williams et al., 2002) . Array CGH detected homozygous deletion of gene region 9p21 containing CDKN2A in cell lines DSH1 and SD. These deletions have been reported by us previously, as have homozygous deletions in 253J, RT112, RT4, SW1710, UM-UC-3 and VMCUB2 (Williams et al., 2002) . The latter six deletions were not detected by array CGH as none of the clones on the array contain the CDKN2A gene and the deletions do not extend to the adjacent clones. This highlights the need for higher density arrays in the future. Homozygous deletion at 9q33.1 containing DBC1 was detected in DSH1 as expected (Williams et al., 2002) . Monosomy 10 and deletion of 10q have been described in bladder tumours using cytogenetics (Smeets et al., 1987) , conventional CGH (Kallioniemi et al., 1992) and FISH (Wang et al., 1994) , and LOH on 10q has frequently been associated with tumour progression Cappellen et al., 1997; Kagan et al., 1998) . The critical regions mapped in these studies have pinpointed PTEN as the tumour suppressor gene located on 10q23.3. Here 52% of cell lines showed loss of chromosome 10 or all or part of 10q, and homozygous deletions were detected at 10q23.31 in J82 and UM-UC-3. Both deletions involved single, different and adjacent clones (bA765C10 in J82 and bA165M8 in UM-UC-3) mapping to the critical region of LOH between markers D10S1644 and D10S541 previously defined in bladder tumours (Kagan et al., 1998) . The only gene in the region between clones bA765C10 and bA165M8 is PTEN. This confirms our previous finding of intragenic homozygous deletion of PTEN in these cell lines . Interestingly, we also found deletions of 10p in six cases. Most conventional CGH studies have reported gains and amplifications of 10p in TCC, so this was a surprising finding. However, 10p LOH has been reported in 38% of advanced TCC (Sengelov et al., 2000) , and loss of 10p was found to accompany transformation of the SV40-immortalized urothelial cell line SV-HUC following transfection with mutant HRAS (Pratt et al., 1992) , indicating that this event may be associated with a more aggressive phenotype as exemplified by the cell lines studied here.
Other frequent losses involved 2q, 3p, 4p, 6p, 6q, 13q, 17p and 18q all of which have been identified previously in TCC samples by either conventional CGH or LOH analysis. For several of these regions, our data provide more precise localization of critical regions, some of which are very small and may now be explored in more detail.
We detected frequent copy number gains on 3q, 20p and 20q, and 15 high-level amplifications. Amplifications of seven of these regions have been identified previously by conventional CGH in bladder tumours (3p25, 6p22.3, 8q22.2-22.3, 10q22.2-q22.3, 11q13.3, 11q22.1-q22.3, 20q13.13-q13 .2) Hovey et al., 1998; Koo et al., 1999; Simon et al., 2000) , and eight (1p13.3-p21.1, 1p21.3-p22.1, 1p34.2-p34.3, 3q11.1, 3q21.21-q21.3, 6p21.1-p21.2, 14q22.3-q23.2, 17p11.2-p12) represent novel findings. These small regions of high-level amplification are of particular interest as they may harbour oncogenes whose overexpression contributes to bladder cancer initiation and/ or progression. Currently, no known candidate oncogenes have been identified in any of the eight novel regions, all of which are small and suitable for immediate candidate gene analysis.
Several candidate genes within previously described amplicons were confirmed to be present within the amplicons mapped here, including RAF1 at 3p25, cyclin D1 at 11q13.3 and ZNF217, BCAS and CYP24 at 20q13.2, the latter previously mapped most precisely in breast tumours (Albertson et al., 2000; Collins et al., 2001) . At 11q22.1-q22.3, several matrix metalloproteinases (MMPs) and the anti-apoptosis genes BIRC2 and BIRC3 have been proposed as candidates in studies of lung (Dai et al., 2003) , cervical (Heselmeyer et al., 1997) and oesophageal cancers (Imoto et al., 2001) , where amplification was found in squamous cell carcinomas (SCCs) in each case. SCaBER, the TCC cell line with this amplicon, was also established from an SCC, indicating that an oncogene within this amplicon may be relevant to the development of SCC in many tissues.
Gains of 20q and some high-level amplifications have been reported previously in many cancers including bladder (Kallioniemi et al., 1995; Richter et al., 1998) , colon, ovarian and breast (reviewed in Hodgson et al., 2003) . Gains of 20q were the second most frequent feature observed here (78%) and gains of 20p were also common (56%). Association of gains of 5p and 20q was reported by Bruch et al. (1998) , and the current study has revealed an association between gain of 5p and chromosome 20 or 20q in 10 of the bladder cancer cell lines analysed.
The most frequent amplification detected was at 6p22.3, in four cell lines. Amplification at 6p22 has previously been detected in bladder tumours and cell lines analysed by conventional CGH (Bruch et al., 1998 (Bruch et al., , 2000 Kallioniemi et al., 1995) . Bruch et al. (2000) detected high-level amplification of 6p in 5637, TCC-SUP and HT1376 and one other TCC cell line not analysed in the present study. Using overlapping YAC clones as FISH probes, a minimum region of amplification covering approximately 2 Mb of 6p22 was identified, which corresponds well with the region delineated here (see Figure 5 ). However, it was not possible to identify precisely the genes within this critical region. The use on our array of clones derived from the human genome sequence tiling path has allowed us to identify unambiguously the candidate genes within this amplicon. Two of these, SOX4 and PRL, were assessed by Bruch et al., who found no relationship of expression to the presence of the 6p22 amplicon. Our real-time PCR results for these genes were similar. However, one of the three other Ensembl genes we analysed, NM_017774, showed clearest amplicon-related expression in tumour cell lines. Thus, NM_017774 is a putative bladder oncogene, although there is at present no information regarding its likely function.
We analysed one normal urothelium-derived cell line, SV-HUC. This line had the least copy number changes but nevertheless there were 10 rearrangements involving gains of 1q, 5q, 8q, 16q and 20q, and loss of 3p, 5p, 6p, 11p and 15q. This is probably a reflection of the effect on genomic stability of the loss of p53 function. The majority of the cell lines were derived from muscle invasive bladder tumours. It is not surprising therefore that some of the genetic changes identified were complex. However, some differences in the frequency and type of change were noted. For example one cell line, 253J, showed predominantly whole chromosome copy number changes and relatively few intrachromosomal breakpoints. Some showed large numbers of breakpoints and several regions of amplification (e.g. SCaBER, SD). Such differences may reflect underlying differences in the ability of the cells to maintain genomic integrity. It will be of great interest in future studies to relate patterns of genomic change to other known genetic characteristics and the phenotype of tumours.
Theoretically, the resolution of this array is p1 Mb and this allows small regions of copy number change to be identified. To make full use of this resolution, it is essential that changes in fluorescence ratios for single clones can be regarded as significant. For this reason, it is important that all clones on the array provide accurate reporting of copy number and that nonspecific noise is minimized. The array has already been subjected to extensive testing (Fiegler et al., 2003) and this together with the present validation on several samples with known genotype, including some small homozygous deletions, provides confidence that the many single-clone changes identified here are worthy of follow-up and this work is currently underway.
A difficult challenge as this technology is applied will be to differentiate biologically relevant events from random but nevertheless clonal events that may occur and be selected at the same time as biologically significant events. Initially, frequency in the tumour population will provide guidance, but ultimately less frequent events that characterize specific tumour subsets will need to be characterized. Methods to manage and interrogate this complex information will therefore be crucial for full exploitation of the potential of these genomic arrays. The present study has provided a foretaste of the complexity that will be defined.
We have shown array CGH to be a sensitive and accurate method for the detection of genome-wide copy number changes, limited only by the size and spacing of large insert clones on the array. This analysis of bladder cancer cell lines has provided a critical assessment of the method's ability to detect known copy number changes and has both refined the localization of several known regions of copy number change in TCC and assisted in candidate gene identification within these. Most importantly, novel features have been identified, some involving only one or a small number of clones, within which genes with important roles in TCC development may lie. The high resolution achieved and the direct links to the genome sequence will considerably reduce the time now required for gene identification.
Materials and methods

Cell lines and culture conditions
Twenty two bladder tumour-derived cell lines (253J, 5637, 647-V, 97-1, BC-3C, BFTC905, BFTC909, DSH1, T24, HT1197, HT1376, J82, JO 0 N, RT112, RT4, SCaBER, SD, SW1710, TCC-SUP, UM-UC-3, VMCUB2 and VMCUB3), one SV40 large T antigen immortalized urothelial cell line (SV-HUC) (Christian et al., 1987) , two normal human urothelium-derived cell lines (NHU262 and NHU267) and 2 normal lymphoblastoid cell lines (HRC160 and HRC575, ECACC) were used in this study. Cell lines were grown under standard cell culture conditions in the following media: minimum essential medium Eagle (Sigma, Dorset, UK) supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine (L-glut) and 1% nonessential amino acids (NEAA) (HT1197, HT1376, J82); Dulbecco's Modified Eagle's Medium (DMEM) (Sigma) supplemented with 10% FBS and 1% L-glut (647-V, BFTC905, BFTC909, T24, TCC-SUP, UM-UC-3, VMCUB2); RPMI 1640 medium (Sigma) supplemented with 10% FBS and 1% L-glut (5637, DSH1, JO 0 N, RT112, SD, SW1710) or 16.6% FBS, 1% L-glut and streptomycin (100 mg/ml) (HRC575, HRC160); DMEM/RPMI supplemented with 5% FBS and 1% L-glut (253J, SCaBER, VMCUB3); McCoy's 5A medium modified (Gibco) supplemented with 10% FBS (BC-3C; RT4); nutrient mixture F12 (Ham) (Gibco) supplemented with 1% FBS, bovine insulin (0.25 U/ml), hydrocortisone (1 mg/ml), FeSO 4 (5 mg/ml), glucose (2.7 mg/ml), 1% L-glut, 1% NEAA, and penicillin/streptomycin (1 Â ) (Cancer Research UK, London, UK) (97-1); DMEM/Ham F12 (Sigma) supplemented as above (SV-HUC); keratinocyte-SFM (Gibco) supplemented with bovine pituitary extract (50 mg/ml), recombinant epidermal growth factor (2 ng/ml) and Cholera toxin (30 ng/ml) (Sigma) (NHU262, NHU267).
CGH arrays
1-Mb resolution whole-genome arrays were produced as described previously (Fiegler et al., 2003) . Briefly, 3040 BAC/ PAC clones from libraries held at the Wellcome Trust Sanger Institute were selected from the published Golden Path available at the time of selection. These clones covered each chromosome with the exception of the short arms of acrocentric chromosomes at an approximate spacing of 1 Mb. Drosophila BAC clones were selected for use as nonspecific hybridization controls and obtained from the RPCI-98 library (http://www.chori.org/bacpac/). Clone details can be obtained on request, and locations can be viewed using the Ensembl genome browser (http://www.ensembl.org/Homo_sapiens/Cytoview). DNA was isolated from BAC/PAC clones, amplified using DOP-PCR and spotted in duplicate onto 3-D link activated slides (Motorola, Schaumburg, IL, USA) using a MicroGrid II arrayer (BioRobotics, Boston, MA, USA).
Genomic DNA isolation, labelling and hybridization to microarrays Genomic DNA was extracted from the lymphoblastoid cell lines HRC160 and HRC575 using a Blood and Cell Culture DNA Mini Kit (Qiagen, Crawley, UK). All other cell line DNA was extracted using a standard proteinase K digestion followed by phenol/chloroform extraction . Array CGH was performed as described previously (Fiegler et al., 2003) . Briefly, test (bladder-derived cell line) and reference (normal lymphoblastoid cell line) genomic DNAs (0.45-1.2 mg) were labelled with Cy3-dCTP or Cy5-dCTP using random-primer labelling (BioPrime DNA Labelling Kit, Invitrogen Ltd, Paisley, UK). Unincorporated nucleotides were removed using Micro-spin G50 columns (Amersham Biosciences UK Ltd, Chalfont St Giles, UK). Labelled DNAs were combined, mixed with 135 mg of human CotI DNA (Invitrogen Ltd), precipitated using ethanol and resuspended in hybridization buffer (50% formamide, 10% dextran sulphate, 0.1% Tween 20, 2 Â SSC, 10 mM Tris-HCl pH7.4). Yeast tRNA (600 mg) (Invitrogen Ltd) was added and the samples were then denatured at 721C for 10 min and incubated at 371C for 60 min. A rubber cement ring was applied around the array (size 2 cm Â 3 cm) to form a well, and slides were prehybridized by the addition of 140 ml of hybridization buffer containing denatured herring sperm DNA (880 mg) (Sigma) and CotI DNA (135 mg) followed by incubation at 371C for 60 min in a humid chamber. Following removal of most of the pre-hybridization solution, the prehybridised genomic DNA was added, the slide was placed in a slide mailer containing Whatmann 3MM paper saturated with 2x SSC and 20% formamide, sealed with parafilm and incubated on a rocking platform (5 r.p.m.) at 371C for 48 h. Slides were washed in PBS/0.1% Tween 20 for 10 min at room temperature, 50% formamide/2 Â SSC for 30 min at 421C, and PBS/0/1% Tween 20 for 10 min at room temperature, and then dried by centrifugation at 150 g for 5 min.
Image acquisition and data analysis
Slides were scanned using an Axon 4000B scanner (Axon Instruments, Burlingame, CA, USA) and images were analysed using UCSF SPOT software (Jain et al., 2002) , which defines spots and calculates background subtracted fluorescence intensities. These fluorescence intensities were then imported into a custom-designed Excel spreadsheet. The spreadsheet (1) excludes data values below the fluorescence intensity values of Drosophila control spots, (2) adjusts for differences in overall signal intensity between Cy3 and Cy5 channels by normalizing all signal intensities to a 1 : 1 ratio on autosomal chromosome clones, (3) calculates mean log 2 (test/reference) ratios for duplicate spots (discarding data with 420% difference) and (4) produces graphical outputs in the form of individual chromosome plots of mean log 2 ratio against distance along the chromosome (Mb). Mapping distances used in the spreadsheet were obtained from the Ensembl database September 2002 update. Chromosome copy number changes were scored as gains or losses when the normalised mean log 2 ratio was above or below 70.2, respectively. Amplifications were classified as those regions where the normalized mean log 2 ratio was above 1.2. Copy number changes involving whole sex chromosomes were not included in the analysis.
FISH
BAC and PAC clones selected for confirmation of array CGH results were grown overnight in 10 ml of TY medium containing the appropriate antibiotic. Cells were spun down and DNA extracted from cell pellets as described (www.sanger.ac.uk/ HGP/methods/cytogenetics/). Clone DNAs were labelled with either biotin-14-dATP or digoxigenin-11-dUTP using the Nick Translation Probe Labelling Kit (Intergen, Burlington, MA, USA) according to the manufacturer's instructions. Metaphase spreads of bladder tumour cell lines RT112, 5637 and 647-V were prepared using standard procedures and FISH was performed essentially as described by Randerson-Moor et al. (2001) . Posthybridization, slides were washed in 2 Â SSC at 721C then in 2 Â SSC at room temperature. Blocking to prevent nonspecific binding was performed by addition of 100 ml of SSCTM (4 Â SSC, 0.05%Tween 20, 5% low fat dried milk) under a coverslip followed by incubation at 371C for 10 min. Slides were washed in 4 Â SSCT at room temperature prior to incubation with 5 mg/ml FITC-conjugated avidin DCS (Vector Laboratories, Peterborough, UK) and 2 mg/ml rhodamine-conjugated anti-digoxigenin (Roche Diagnostics, Lewes, UK) for 10 min at 371C. Following washes in 4 Â SSCT and PBS at room temperature, slides were mounted in Citifluor (Citifluor Ltd, London, UK) containing DAPI (Cambio Ltd. Cambridge, UK), viewed using a Zeiss Axioskop microscope (Zeiss, Jena, Germany) and images captured and analysed using SmartCapture 2 (Digital Scientific, Cambridge, UK).
M-FISH
Metaphase chromosomes were prepared using standard procedures. M-FISH was carried out using the Spectravision Assay system (Vysis, Downers Grove, IL, USA) according to the manufacturer's instructions. Metaphases were captured and analysed using Spectravision software (Vysis).
Total RNA isolation, cDNA synthesis and real-time PCR A sub-panel of cell lines was selected for real time PCR expression analysis of the candidate genes (E2F3, SOX4, Q9H1N9, PRL, NM_017774) located in the 6p22.3 amplicon. These were: NHU262, NHU267, 5637, 647-V, BFTC905, BFTC909, HT1376, J82, JO 0 N, RT112, SCaBER, SD, TCC-SUP, VMCUB2 and VMCUB3. Total RNA was extracted from cultured cells using TRIZOL (Invitrogen Ltd) according to the manufacturer's protocol. cDNA was synthesized from 1 mg of total RNA using an Advantage RT-for-PCR Kit (BD Biosciences, Oxford, UK) and oligo-dT as primer. Primer Express Sequence Design Software (Applied Biosystems, Warrington, UK) was used to design primers to candidate genes and control genes (HPRT1 and B2M). Primer sequences are available on request. Real time PCRs were performed in triplicate in 25 ml reactions containing 12.5 ml SYBR s Green PCR Master Mix (Applied Biosystems), 200 nM forward and reverse primers and approximately 1 ng of template. Thermal cycling conditions for the ABI 7700 (Applied Biosystems) were 501C for 2 min, 951C for 10 min, 40 cycles of 951C for 15 s and 601C for 1 min, 951C for 15 s and finally 601C for 20 s. Relative levels of expression were determined using the comparative C T method as described in Applied Biosystems User Bulletin x2 with samples normalized to NHU262.
